Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

US8715638B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Southern Research Institute · US

Inventors

• Cecil D. Kwong · Decatur, US
• F. George Njoroge · Hackettstown, US
• Subramaniam Ananthan · Birmingham, US
• Jeremy Clark · Birmingham, US
• Feng Geng · Hamburg, DE
• Hollis S. Kezar, III · Hoover, US
• Joseph A. Maddry · Birmingham, US
• John J. Piwinski · Lebanon, US
• Robert C. Reynolds · Birmingham, US
• Abhijit Roychowdhury · Birmingham, US
• John A. Secrist, III · Birmingham, US
• Neng-Yang Shih · Lexington, US

Key dates

• Filing date: Aug 19, 2009
• Grant date: May 6, 2014
• Expiry date: Sep 2, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19, R22, R23, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.